Literature DB >> 2432177

Presynaptic serotonergic dysfunction in patients with Alzheimer's disease.

A M Palmer, P T Francis, J S Benton, N R Sims, D M Mann, D Neary, J S Snowden, D M Bowen.   

Abstract

Indices of presynaptic serotonergic nerve endings were assayed in neocortical biopsy samples from patients with histologically verified Alzheimer's disease. The concentrations of 5-hydroxytryptamine (serotonin) and 5-hydroxyindoleacetic acid, serotonin uptake, and K+-stimulated release of endogenous serotonin were all found to be reduced below control values. Changes occurred in samples from both the frontal and temporal lobes, but they were most severe (at least a 55% reduction) in the temporal lobe. This is indicative of substantial serotonergic denervation. Values for serotonergic markers in Alzheimer's disease samples did not show correlations with rating of the severity of dementia, indices of cholinergic innervation, or senile plaque and cortical pyramidal neurone loss. However, neurofibrillary tangle count and an index of glucose oxidation (both probably reflecting pyramidal cells) correlated with the concentration of 5-hydroxyindoleacetic acid.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432177     DOI: 10.1111/j.1471-4159.1987.tb13120.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

1.  Different changes in concentrations of monoamines and their metabolites and amino acids in various brain regions by the herbal medicine/Toki-Shakuyaku-San between female and male senescence-accelerated mice (SAMP8).

Authors:  M Komatsu; Y Ueda; M Hiramatsu
Journal:  Neurochem Res       Date:  1999-07       Impact factor: 3.996

2.  Treating behavioural and psychological signs in Alzheimer's disease.

Authors:  C Ballard; J O'Brien
Journal:  BMJ       Date:  1999-07-17

3.  Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.

Authors:  A W Procter; P T Francis; G C Stratmann; D M Bowen
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

Review 4.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 5.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 6.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

7.  Trans-synaptic stimulation of cortical acetylcholine release after partial 192 IgG-saporin-induced loss of cortical cholinergic afferents.

Authors:  J Fadel; H Moore; M Sarter; J P Bruno
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

Review 8.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Serotonin reduction in the mouse neostriatum during hyperthermia-induced convulsions studied by immunohistochemistry.

Authors:  Y Takeuchi; K Fujiwara; K Ishimura; H Yoshioka; T Sawada
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 10.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.